| Jessica Jameson Deane-wyman, MD | |
|
2100 S Tryon St, Ste 201, Charlotte, NC 28203-4958 | |
| (704) 316-3000 | |
| (704) 316-3001 |
| Full Name | Jessica Jameson Deane-wyman |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 14 Years |
| Location | 2100 S Tryon St, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366769044 | NPI | - | NPPES |
| 1366769044 | Medicaid | NC | |
| NC2198 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 164466 (North Carolina) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 2014-00173 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novant Medical Group Inc | 1153234893 | 1996 |
News Archive
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
Following the closure of several research programs for Alzheimer's disease, in early 2018 the FDA issued a release entitled "Draft Guidance for Industry: Early Alzheimer's Disease: Developing Drugs for Treatment." Encouraged by the proposed changes in the new guidance, Genervon's research team reported new findings that its drug candidate GM6 attenuates Alzheimer's disease in an early AD transgenic APP mice model.
Without following a particular diet, overweight people who tracked daily food consumption using a free smartphone app lost a significant amount of weight in a new Duke University study.
› Verified 7 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
Following the closure of several research programs for Alzheimer's disease, in early 2018 the FDA issued a release entitled "Draft Guidance for Industry: Early Alzheimer's Disease: Developing Drugs for Treatment." Encouraged by the proposed changes in the new guidance, Genervon's research team reported new findings that its drug candidate GM6 attenuates Alzheimer's disease in an early AD transgenic APP mice model.
Without following a particular diet, overweight people who tracked daily food consumption using a free smartphone app lost a significant amount of weight in a new Duke University study.
› Verified 7 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306950282 PECOS PAC ID: 1153234893 Enrollment ID: O20040204001028 |
News Archive
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
Following the closure of several research programs for Alzheimer's disease, in early 2018 the FDA issued a release entitled "Draft Guidance for Industry: Early Alzheimer's Disease: Developing Drugs for Treatment." Encouraged by the proposed changes in the new guidance, Genervon's research team reported new findings that its drug candidate GM6 attenuates Alzheimer's disease in an early AD transgenic APP mice model.
Without following a particular diet, overweight people who tracked daily food consumption using a free smartphone app lost a significant amount of weight in a new Duke University study.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Jameson Deane-wyman, MD Po Box 60447, Charlotte, NC 28260-0447 Ph: (704) 316-3000 | Jessica Jameson Deane-wyman, MD 2100 S Tryon St, Ste 201, Charlotte, NC 28203-4958 Ph: (704) 316-3000 |
News Archive
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
Following the closure of several research programs for Alzheimer's disease, in early 2018 the FDA issued a release entitled "Draft Guidance for Industry: Early Alzheimer's Disease: Developing Drugs for Treatment." Encouraged by the proposed changes in the new guidance, Genervon's research team reported new findings that its drug candidate GM6 attenuates Alzheimer's disease in an early AD transgenic APP mice model.
Without following a particular diet, overweight people who tracked daily food consumption using a free smartphone app lost a significant amount of weight in a new Duke University study.
› Verified 7 days ago
Jackie Alan Lucas, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 450, Charlotte, NC 28204 Phone: 704-446-7800 | |
Lynn Amy Boardman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Dr. Simon Vivian Ward Iii, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1918 Randolph Rd, Suite 670, Charlotte, NC 28207 Phone: 704-384-1620 Fax: 704-384-1626 | |
Curtis Lee Flood, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6331 Carmel Rd Ste 102, Charlotte, NC 28226 Phone: 980-367-4363 Fax: 704-316-2558 | |
Grant Blanchard, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Roland Pixley, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 400, Charlotte, NC 28204 Phone: 704-446-1700 | |
Katherine Elizabeth Akeley, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 |